Literature DB >> 15011175

Alternative graft materials for hemodialysis access.

Larry A Scher1, Howard E Katzman.   

Abstract

Since the initial description of the arteriovenous (AV) fistula, autogenous access has been the procedure of choice for chronic hemodialysis. Recently established National Kidney Foundation Dialysis Outcome and Quality Initiative guidelines have validated the superiority of arteriovenous fistulas over AV grafts but have also addressed the fact that a significant percentage of the growing dialysis population does not have veins suitable for primary AV fistulas. Recent advances in forearm, upper arm, and femoral venous transpositions have facilitated the performance of increased numbers of autogenous access procedures. Nevertheless, substantial numbers of patients on chronic hemodialysis require prosthetic AV grafts. Since early reports describing hemodialysis access using expanded polytetrafluoroethylene, surgical results with prosthetic graft materials have remained suboptimal. Modifications in polytetrafluoroethylene grafts and the recent development of alternative graft materials for hemodialysis access have yielded encouraging early results in efforts to improve patency of AV grafts. We will review currently available graft materials and recent developments in an ongoing effort to improve the results with prosthetic and biologic hemodialysis access conduits.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15011175     DOI: 10.1053/j.semvascsurg.2003.11.007

Source DB:  PubMed          Journal:  Semin Vasc Surg        ISSN: 0895-7967            Impact factor:   1.000


  2 in total

1.  Patency rates of cuffed and noncuffed extended polytetrafluoroethylene grafts in dialysis access: a prospective, randomized study.

Authors:  Po-Jen Ko; Yun-Hen Liu; Yen-Ni Hung; Hung-Chang Hsieh
Journal:  World J Surg       Date:  2009-04       Impact factor: 3.352

Review 2.  Update on kidney transplantation for the urologist.

Authors:  H Albin Gritsch
Journal:  Curr Urol Rep       Date:  2005-02       Impact factor: 2.862

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.